TWI730027B - 稠合四環化合物及其組合物與用途 - Google Patents

稠合四環化合物及其組合物與用途 Download PDF

Info

Publication number
TWI730027B
TWI730027B TW106100215A TW106100215A TWI730027B TW I730027 B TWI730027 B TW I730027B TW 106100215 A TW106100215 A TW 106100215A TW 106100215 A TW106100215 A TW 106100215A TW I730027 B TWI730027 B TW I730027B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
pyrrolo
mmol
Prior art date
Application number
TW106100215A
Other languages
English (en)
Chinese (zh)
Other versions
TW201726681A (zh
Inventor
凱西 卡麥隆 摩可摩斯
麥可 H 薩瑞諾－吳
喬瑟夫 P 維卡
Original Assignee
美商泰博生物科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商泰博生物科技股份有限公司 filed Critical 美商泰博生物科技股份有限公司
Publication of TW201726681A publication Critical patent/TW201726681A/zh
Application granted granted Critical
Publication of TWI730027B publication Critical patent/TWI730027B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW106100215A 2016-01-04 2017-01-04 稠合四環化合物及其組合物與用途 TWI730027B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662274640P 2016-01-04 2016-01-04
US62/274,640 2016-01-04

Publications (2)

Publication Number Publication Date
TW201726681A TW201726681A (zh) 2017-08-01
TWI730027B true TWI730027B (zh) 2021-06-11

Family

ID=59226993

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106100215A TWI730027B (zh) 2016-01-04 2017-01-04 稠合四環化合物及其組合物與用途

Country Status (9)

Country Link
US (2) US10059718B2 (enExample)
EP (1) EP3400228B1 (enExample)
JP (1) JP7068185B2 (enExample)
CN (1) CN108779123B (enExample)
AU (1) AU2017205320B2 (enExample)
CA (1) CA3010213A1 (enExample)
ES (1) ES2915901T3 (enExample)
TW (1) TWI730027B (enExample)
WO (1) WO2017120164A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059718B2 (en) 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof
CN107879989B (zh) * 2017-11-29 2020-01-03 重庆市中药研究院 具有生物活性的3,4,5-取代苯并二氮卓2-酮类药物分子及其制备方法
CN118574834A (zh) * 2021-01-11 2024-08-30 泰博生物科技股份有限公司 稠合的四环化合物、其组合物和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040487A2 (en) 2000-11-16 2002-05-23 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as gaba a receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521534A (en) 1983-12-19 1985-06-04 Ayerst, Mckenna & Harrison, Ltd. Imidazo[2,1-a]pyrrolo[2,1-c][1,4]benzodiazepine derivatives, methods of preparation and use
US4596799A (en) 1985-01-29 1986-06-24 Ciba-Geigy Corporation 9H-pyrrolo[2,1-c]-1,2,4-triazolo[4,3-a][1,4]benzodiazepines
AU2003301226A1 (en) 2002-12-20 2004-07-22 Pharmacia Corp Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2
KR20150133172A (ko) 2013-03-15 2015-11-27 셀진 아빌로믹스 리서치, 인코포레이티드 Mk2 억제제 및 이의 용도
WO2014146164A1 (en) * 2013-03-22 2014-09-25 Lifi Labs Inc Color selection
US10059718B2 (en) 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040487A2 (en) 2000-11-16 2002-05-23 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as gaba a receptor modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAO, A. U. et al., "Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 ( MK 2) inhibitors", Bioorganic & medicinal chemistry letters, vol. 22, no. 2, (20120115), pages 1068 - 1072 *

Also Published As

Publication number Publication date
EP3400228B1 (en) 2022-04-13
ES2915901T3 (es) 2022-06-27
JP2019501971A (ja) 2019-01-24
JP7068185B2 (ja) 2022-05-16
AU2017205320B2 (en) 2021-06-24
EP3400228A1 (en) 2018-11-14
CA3010213A1 (en) 2017-07-13
US20180319809A1 (en) 2018-11-08
EP3400228A4 (en) 2019-08-14
US10059718B2 (en) 2018-08-28
AU2017205320A1 (en) 2018-07-05
CN108779123A (zh) 2018-11-09
WO2017120164A1 (en) 2017-07-13
US10562909B2 (en) 2020-02-18
US20170190713A1 (en) 2017-07-06
CN108779123B (zh) 2025-08-19
TW201726681A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
EP3968999B1 (en) Fgfr inhibitors and methods of use thereof
KR102558540B1 (ko) 테트라사이클린 화합물 및 치료 방법
KR20170031669A (ko) 치환된 우레아 유도체 및 이의 약제학적 용도
JP2025536369A (ja) Ｋｒａｓ ｇ１２ｄ分解剤及びその製造方法並びに応用
CN111527090B (zh) 作为p2x3抑制剂的吡唑并-吡咯并-嘧啶-二酮衍生物
EP4631948A1 (en) Novel tricyclic compound as kras g12d inhibitor, and use thereof
TWI730027B (zh) 稠合四環化合物及其組合物與用途
AU2023286528A1 (en) 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof
TW202417458A (zh) 調節her2的化合物及方法
CN120769855A (zh) 4-氨基吡咯并[2,1-f][1,2,4]三嗪及其制备和用途
CA3213823A1 (en) Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
HK40006173A (en) Fused quadracyclic compounds, compositions and uses thereof
HK40006173B (zh) 稠合四环化合物、其组合物和用途
WO2025231261A1 (en) Bicyclic and heterocyclic amide compounds
TW202515566A (zh) Ｓｍａｒｃａ２降解劑及其用途
JP2025540246A (ja) Ｋｒａｓ ｇ１２ｄ阻害剤として新規な３環化合物およびその用途
CN117980290A (zh) 氰基吡啶和氰基嘧啶bcl6降解剂
WO2024035688A1 (en) Macrocyclic bcl6 degraders
WO2025253326A1 (ko) Kras 저해제로서 신규한 3환 화합물 및 이의 용도
HK40030438A (en) Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors